Ipsen Completes Acquisition of Memo Therapeutics and Secures Potravitug

A First-in-Class Antibody for an Orphan Indication

Potravitug is a monoclonal antibody targeting the reactivation of BK polyomavirus (BKPyV) in kidney transplant recipients. During clinical trials, the compound demonstrated significant antiviral response and resolution of BKPyV-associated nephropathy. These results are based on the phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this population. Additional analyses presented at international nephrology and transplantation congresses further strengthen its clinical profile. Currently, no targeted therapy is approved for BKPyV. Clinical management involves balancing graft protection and virus control by reducing immunosuppression.

A Broad Market Among Transplant Patients

Approximately 90% of kidney transplant recipients are seropositive for BKPyV. High viral loads in the blood affect about 30% of patients during the first year after transplantation. Reactivation of BK polyomavirus and associated nephropathy (BKVAN) can increase the risk of graft loss and the need for dialysis or a new transplantation. More than 100,000 kidney transplants are performed globally each year, including over 28,000 in the United States, where more than 90,000 additional patients are awaiting a transplant.

Integration into Ipsen's Rare Diseases Portfolio

This acquisition strengthens Ipsen's positioning in rare diseases, one of the group's three therapeutic areas. The group operates a portfolio based on internal and external innovation, supported by nearly 100 years of development experience. It has centers of excellence in the United States, France, and the United Kingdom and operates in over 40 countries.